Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

Nienke A. de Vries(The Netherlands Cancer Institute), Maarten van Lohuizen(Oncode Institute), Denise C. Miles(The University of Melbourne), Jos Jonkers(The Netherlands Cancer Institute), Johann de Jong(Boehringer Ingelheim (Germany)), Danielle Hulsman(The Netherlands Cancer Institute), Marleen Blom(The Netherlands Cancer Institute), Waseem Akhtar(Leeds Teaching Hospitals NHS Trust), Olaf van Tellingen(Dutch Cancer Society)
Cell Reports
January 1, 2015
10.1016/j.celrep.2014.12.028
Cited by 90

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Molecular Maps of the Reorganization of Genome-Nuclear Lamina Interactions during Differentiation
|Molecular Cell|2010|1.1k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
|Nature Structural & Molecular Biology|2010|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941